Skip to content
Drugs Targeting ALKGabriele Wright2024-04-19T11:21:32-05:00
Drugs Targeting ALK
- Alecensa (alectinib) – approved for stage 1B-3A NSCLC patients following complete surgical resection and stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.
- Alunbrig (brigatinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test who have progressed on another ALK targeted therapy.
- Lobrena (lorlatinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test and who have progressed on at least two other ALK targeted therapies.
- Xalkori (crizotinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.
- Zykadia (ceritinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.
